DJ
Therapeutic Areas
Ocean Biomedical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OCEA-001 (anti-CSPG4 mAb) | Non-Small Cell Lung Cancer (NSCLC), Melanoma | Phase 1b/2 |
| B7-H3 Targeted Antibody | Solid Tumors | Preclinical |
| GMZ2.6C Fusion Protein | Malaria Prevention & Treatment | Preclinical |
| Fibrosis Small Molecule Program | Idiopathic Pulmonary Fibrosis (IPF), Liver Fibrosis | Discovery/Preclinical |
Leadership Team at Ocean Biomedical
DC
Dr. Chirinjeev Kathuria, MD
Co-Founder and Executive Chairman
DS
Dr. Suren Ajjarapu, PhD
Co-Founder, Chief Executive Officer, and Chairman
EN
Elizabeth Ng
Chief Financial Officer
DM
Dr. Michael J. Manyak, MD
Chief Medical Officer
DJ
Dr. Jake Kurtis, PhD
Scientific Founder, Director of Center for International Health Research at Brown University
DB
Dr. Bharat Ramratnam, MD
Co-Founder and Chief Scientific Officer
DI
Dr. Inder Singh
Board Director